Targeted therapeutic effect of anti-ABCG2 antibody combined with nano silver and vincristine on mouse myeloma cancer stem cells
Source abstract
Abstract
Studies from hematopoietic origin malignancies have demonstrated that multiple myeloma contain a rare population of cancer stem cells (CSCs) that are responsible for tumor multiresistance and recurrence. The goal of this study was to investigate targeted therapeutic effect of anti-ABCG2 monoclonal antibody (McAb) combined with silver nanoparticles (AgNPs) and vincristine (VCR) on myeloma CSCs. The characteristics of CD44+ CD24− cells that were isolated from the SP2/0 cells using magnetic activated cell sorting system were first identified. The results showed that the CD44+ CD24− cells exhibited higher proliferation, more colony formation, more side population fraction, and stronger tumorigenicity in BALB/c mice than the control cells. Moreover, CD44+ CD24− cells markedly up-regulated the ABCG2 expression, however, anti-ABCG2 McAb combined with AgNPs and VCR effectively inhibited the CD44+ CD24− cell growth and prolonged the survival of myeloma-bearing mice. We concluded that the CD44+ CD24− cells in mouse myeloma SP2/0 cell line posses CSC properties. Anti-ABCG2 McAb combined with AgNPs and VCR provide an efficient targeted therapeutic method for inhibiting myeloma CD44+ CD24− CSC growth in mice.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Glycosylation and Glycoproteins Research · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N (2012) Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst 104:1005–102010.1093/jnci/djs257 ↗
2. Carsten MT, Ralf M, Katrin K (2001) Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 61:647–653
3. Chen J, Wang J, Chen D (2013) Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol 14:710.1186/1471-2121-14-7 ↗
4. Cirstea D, Hideshima T, Rodig S (2010) Dual inhibition of Akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound–rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9:96310.1158/1535-7163.MCT-09-0763 ↗
5. Deweerdt S (2011) Animal models: towards a myeloma mouse. Nature 480:S38–S3910.1038/480S38a ↗
6. Dou J, Gu N (2010) Emerging strategies for the identification and targeting of cancer stem cells. Tumor Biol 31:243–25310.1007/s13277-010-0023-y ↗
7. Dou J, Li Y, Zhao F, Hu W, Wen P, Tang Q, Jiang C, Gu N (2009) Identification of tumor stem-like cells in a mouse myeloma cell line. Cell Mol Biol (Noisy-le-grand) 55:OL1151–OL1160
8. Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D, Gu N (2011) Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 35:227–23410.1042/CBI20100347 ↗
9. Drain S, Flannely L, Drake MB (2011) Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma. Leuk Res 35:1457–146310.1016/j.leukres.2011.05.033 ↗
10. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE (1976) Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 36:3798–3802
11. Holt RU, Fagerli UM, Baykov V, Rø TB, Hov H, Waage A, Sundan A, Børset M (2008) Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 93:619–62210.3324/haematol.11867 ↗
12. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Mitsiades CS (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117:4409–441910.1182/blood-2010-02-267344 ↗
13. Jun D, Meng P, Ping W (2007) Isolation and identification of cancer stem like cells from murine melanoma cell lines. Cell Mol Immunol 4:467–472
14. Kang SJ, Ryoo IG, Lee YJ, Kwak MK (2012) Role of the Nrf2-heme oxygenase-1 pathway in silver nanoparticle-mediated cytotoxicity. Toxicol Appl Pharmacol 258:89–9810.1016/j.taap.2011.10.011 ↗
15. Khan TM, Benaich N, Malone CF, Bernardos RL, Russell AR, Hutson LD (2012) Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish. J Peripher Nerv Syst 17:76–8910.1111/j.1529-8027.2012.00371.x ↗
16. Kim M, Turnquist H, Jackson J (2002) The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8:22–28
17. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–187310.1056/NEJMra041875 ↗
18. Liu J, Zhao Y, Guo Q, Wang Z, Wang H, Yang Y, Huang Y (2012) TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials 33:6155–616110.1016/j.biomaterials.2012.05.035 ↗
19. Lubna P, Tammy C, Robin SB (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 65:6207–621910.1158/0008-5472.CAN-05-0592 ↗
20. Maranon C, Planelles L, Alonso C (2000) HSP70 from Trypanosoma cruzi is endowed with specific cell proliferation potential leading to apoptosis. Int Immunol 12:1685–169310.1093/intimm/12.12.1685 ↗
21. Matsui W (2011) Perspective: a model disease. Nature 480:S5810.1038/480S58a ↗
22. Matsui W, Huff CA, Wang Q (2004) Characterization of clonogenic multiple myeloma cells. Blood 103:2332–233610.1182/blood-2003-09-3064 ↗
23. Michael D, Tito F, Susan B (2005) Tumor stem cells and drug resistance. Nat Rev 5:275–28410.1038/nrc1590 ↗
24. Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P, Batra SK (2010) MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 29:5741–575410.1038/onc.2010.309 ↗
25. Rapid Mosmann T (1983) Colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–6310.1016/0022-1759(83)90303-4 ↗
26. Rowan K (2009) Are cancer stem cells real? After four decades, debate still simmers. J Natl Cancer Inst 101:546–54710.1093/jnci/djp083 ↗
27. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Frank MH (2008) Identification of cells initiating human melanomas. Nature 451:345–34910.1038/nature06489 ↗
28. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337:730–73510.1126/science.1224676 ↗
29. Su HY, Lai HC, Lin YW (2010) Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127:555–56710.1002/ijc.25083 ↗
30. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis NJ, Morris D (2012) Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res 18:4962–497210.1158/1078-0432.CCR-11-3085 ↗
31. Turner JG, Gump JL, Zhang C (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108:3881–388910.1182/blood-2005-10-009084 ↗
32. Wang J, Cao MG, You CZ, Wang CL, Liu SL, Cai K, Dou J (2012) A preliminary investigation of the relationship between circulation tumor cells and cancer stem cells in patients with breast cancer. Cell Mol Biol 58(supp):OL1641–OL1645
33. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Tricot G (2013) RARα2 expression confers myeloma stem cell features. Blood 122:1437–144710.1182/blood-2013-02-482919 ↗